Cancer
Malignant Esophageal Neoplasm
CI-CAN-00001127Explore in graph →
Top-level518 active trials6 approved drugs12 evidence items
Loading cancer entity…
Cancer
CI-CAN-00001127Explore in graph →
Clinical trials
1,926 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (169)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00342654 | Nutrition Intervention Trials in Linxian Follow-up Study | completed | — | 32,902 | National Cancer Institute (NCI)NIH | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04359732 | Assessment of Response to nCRT for GEJ Cancer Using a Fully Integrated PET/MRI(Escape) | completed | N/A | 121 | IRCCS San RaffaeleOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT00911092 | Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer(COL) | completed | Phase 4 | 50 | Centre Oscar LambretOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT00341276 | Esophageal Cancer Genetics Studies | completed | — | 7,705 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT00450788 | Esophageal Cancer in Northeastern Iran | completed | — | 50,045 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04543617 | A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy(SKYSCRAPER-07) | completed | Phase 3 | 760 | Hoffmann-La RocheINDUSTRY | 28 | Sep 14, 2026 | clinicaltrials |
| NCT04921904 | Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca | completed | Phase 1 / Phase 2 | 26 | Baylor Research InstituteOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05858736 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors(PRESERVE-009) | completed | Phase 1 | 18 | OncoC4, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05281380 | VITAMin Insufficiency in Esophagogastric Neoplasms(VITAMIN) | completed | N/A | 107 | Zuyderland Medisch CentrumOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06790355 | ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population | completed | N/A | 2,527 | Shanghai Weihe Medical Laboratory Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05864144 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 98 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04540211 | A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma(SKYSCRAPER-08) | completed | Phase 3 | 461 | Hoffmann-La RocheINDUSTRY | 5 | Aug 27, 2026 | clinicaltrials |
| NCT04670445 | Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer(UPLIFT) | completed | N/A | 199 | Massachusetts General HospitalOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07549269 | Comparison of Nab-Paclitaxel Versus Paclitaxel in Neoadjuvant Immunochemotherapy Therapy for Esophageal Squamous Cell Carcinoma: A Retrospective IPTW-Adjusted Analysis | completed | — | 387 | Sichuan UniversityOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07488624 | Survival Prediction After Neoadjuvant Chemoimmunotherapy and Esophagectomy for Esophageal Squamous Cell Carcinoma | completed | — | 414 | Sichuan UniversityOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT00333099 | INEC Study: Immuno-modulating Enteral Nutrition in Cancer | completed | Phase 4 | 250 | University Hospital, Clermont-FerrandOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06281886 | Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma | completed | Phase 2 | 170 | Sun Yat-sen UniversityOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT00183898 | Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer | completed | Phase 2 | 75 | University of Southern CaliforniaOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04210115 | Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) | completed | Phase 3 | 703 | Merck Sharp & Dohme LLCINDUSTRY | 27 | Jul 22, 2026 | clinicaltrials |
| NCT07705412 | Postoperative Radiotherapy and Lymph Node Dissection After Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma | completed | — | 465 | Tongji HospitalOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05538195 | Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors | completed | Phase 1 / Phase 2 | 17 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05415475 | Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors | completed | Phase 1 | 30 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 9, 2026 | clinicaltrials |
| NCT05708950 | A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | completed | Phase 1 / Phase 2 | 40 | Kineta Inc.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05964361 | First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer Patients(IL15-TransDC) | completed | Phase 1 / Phase 2 | 10 | University Hospital, AntwerpOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT01196390 | Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer | completed | Phase 3 | 203 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2026 | clinicaltrials |
| NCT04183218 | Characterizing Chemo-Radiotherapy Treatment-Related Cardiac Changes | completed | — | 24 | Mayo ClinicOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT04984733 | Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer(ELEVATE) | completed | Phase 2 | 13 | University of SouthamptonOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT04776837 | Predicting Disease Progression and/or Recurrence in Cancer | completed | — | 159 | Massachusetts General HospitalOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT00937456 | Open Versus Laparoscopically-assisted Esophagectomy for Cancer | completed | N/A | 207 | University Hospital, LilleOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT07312526 | Shanghai Clinical Cohort - Esophageal Cancer | completed | — | 2,116 | Shanghai Chest HospitalOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02606396 | Cryotherapy for Malignant Dysphagia in Patients With Advanced Esophageal Cancer | completed | N/A | 15 | Hunter Holmes Mcguire Veteran Affairs Medical CenterFED | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03102229 | Real-time Activity Monitoring to Prevent Admissions During RadioTherapy(RAMPART) | completed | N/A | 40 | Montefiore Medical CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05450484 | Quantitative Fluorescence Endoscopy Using Durvalumab-680LT in Esophageal Cancer(OPTIC) | completed | Phase 1 | 21 | University Medical Center GroningenOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05461430 | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)(TraveraRTGx) | completed | — | 72 | Travera IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04785820 | A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus | completed | Phase 2 | 190 | Hoffmann-La RocheINDUSTRY | 18 | Mar 27, 2026 | clinicaltrials |
| NCT05411133 | Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | completed | Phase 1 | 33 | Arbele Pty LtdINDUSTRY | 2 | Mar 19, 2026 | clinicaltrials |
| NCT02642809 | Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers | completed | Phase 1 | 16 | Washington University School of MedicineOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT03322267 | Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence | completed | Phase 2 | 26 | National Taiwan University HospitalOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04426669 | A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering | completed | Phase 1 / Phase 2 | 23 | Intima Bioscience, Inc.INDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT07184047 | Frailty Scales for Predicting Chemotherapy Toxicity in Older Adults With Gastrointestinal Cancers(TOX-FRAIL) | completed | — | 72 | Ankara Etlik City HospitalOTHER_GOV | 1 | Feb 20, 2026 | clinicaltrials |
| NCT03896399 | Laparoscopic Ischemic Conditioning Prior to Esophagectomy(ISCON) | completed | N/A | 22 | UMC UtrechtOTHER | 2 | Feb 19, 2026 | clinicaltrials |
| NCT07416825 | Inter-Observer Delineation Differences in Esophageal Cancer GTV on MR, CT, and PET/CT Protokol šečerov Ermenc 28dec19 | completed | N/A | 23 | Institute of Oncology LjubljanaOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT03993353 | Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer | completed | Phase 2 | 7 | University of California, San DiegoOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05787522 | Clinical Validation of AI-Assisted Radiotherapy Contouring Software for Thoracic Organs at Risk | completed | — | 500 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT06027515 | Esophageal Cancer Multimodal Prehabilitation Study | completed | N/A | 15 | Massachusetts General HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT00628368 | Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer | completed | N/A | 160 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT04217239 | A Comparison Between Ivor-Lewis and McKeown Minimally Invasive Esophagectomy | completed | N/A | 272 | The Second Hospital of Shandong UniversityOTHER | 1 | Feb 5, 2026 | clinicaltrials |
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials